Doctors sound alarm as drug resistant urinary tract infections rise across the U.S.
Clinicians and infectious disease specialists are reporting a sharp uptick in urinary tract infections that fail standard therapy, a trend public health officials say is part of a broader surge in highly resistant bacteria. The Centers for Disease Control and Prevention found infections from bacteria carrying the NDM resistance gene jumped by more than 460 percent between 2019 and 2023, and noted that urinary tract infections are among the clinical presentations now harder to treat. The change has moved a once-rare threat into routine clinical practice.
What doctors are seeing at the bedside
Physicians describe more patients returning after initial treatment with persistent symptoms, and an increase in laboratory reports of extended-spectrum beta-lactamase producing E. coli and other resistant uropathogens. E. coli remains the dominant cause of community UTIs, but resistance is rising. Pediatric and outpatient surveillance shows ESBL rates edging upward in recent years, shifting empiric prescribing and complicating decisions about oral therapy. At the same time, healthcare-associated risk factors such as urinary catheters and prolonged hospital stays concentrate the problem in vulnerable patients.
Scale, drivers and public health response
CDC and independent investigators counted roughly 4,341 carbapenem-resistant Enterobacterales cases in 2023 from reporting states, with 1,831 linked to the NDM gene. Overall carbapenem-resistant infections rose about 69 percent while NDM-type cases climbed dramatically, signaling both spread and gaps in detection. Experts point to increased antibiotic use during the pandemic, inconsistent testing capacity, and lapses in infection control as likely contributors. Authorities are urging faster diagnostic testing, tighter infection control, and more rigorous antibiotic stewardship.
Treatment options and next steps
New drugs have begun to arrive; the FDA approved the oral antibiotic gepotidacin (Blujepa) for uncomplicated urinary tract infections on March 25, 2025, expanding options for some outpatient cases. Still, specialists stress that new agents are not a substitute for prevention. Hospital programs must prioritize testing, stewardship, and catheter avoidance to blunt spread, and community clinicians should use culture-directed therapy whenever possible to preserve effectiveness.
The consensus among clinicians is clear: this is an urgent, controllable public health problem that requires coordinated action now to prevent routine infections from becoming life threatening.